 The dopamine D1-receptor (D1-R) is of interest in relation to several major psychiatric disorders, however this receptor subtype is less studied than other markers for the dopamine system.  Studies investigating D1-R in psychiatric patients in comparison to healthy control subjects were summarized, including calculating effect sizes based on descriptive data.
Introduction
The dopamine (DA) system is considered to be involved in most aspects of human behaviour, from motor control to cognitive and motivational domains. As a corollary, DA neurotransmission has been a central focus for research on the pathophysiology and treatment of major psychiatric disorders such as schizophrenia, affective disorders and substance use disorders. Positron emission tomography (PET) is a molecular imaging technique which allows for quantification of markers of brain neurotransmission in the living human brain, providing an opportunity to examine DA function in psychiatric populations. The majority of this work has focused on the dopamine D2/D3 receptor subtype (D2/D3-R) and the dopamine transporter [1] [2] [3] [4] . In contrast, the dopamine D1-receptor (D1-R), which is the most abundant receptor subtype in the brain, has received much less attention.
D1-R belongs to the D1/D4/D5 receptor family, which shows opposing intracellular effects compared to D2/D3-R. Whereas D2/D3-R stimulation leads to blockade of cAMP cascade, stimulation of D1/D4/D5-R results in increased cAMP levels [5] . In the striatum, which is the most A C C E P T E D M A N U S C R I P T DA-rich region in the brain, these opposing effects of DA signalling are mainly balanced by the distribution of D1-R predominantly on cells providing output via the direct nigrostriatal pathway whereas D2/D3-R expressing cells project via the indirect pathway [6] . D2/D3-R are found primarily in the striatum, in contrast the D1-R is widely distributed throughout the brain [7] ( Figure   1 ). Finally, D2/D3-R has high affinity for DA, and is considered sensitive to tonic DA levels, whereas the relatively low affinity D1-R may primarily detect phasic changes [8] [9] [10] . These differences in downstream effects, connectivity and localization suggest that D1-R may serve as a functionally distinct marker of the DA system. Indeed, a specific role for D1-R has been suggested for cognitive performance [11] [12] [13] [14] , reward signal processing [15] [16] [17] and response inhibition [18] , all domains that are considered relevant for a range of psychiatric conditions [3, 17, [19] [20] [21] .
The aim of this review is to briefly describe available radioligands for the D1-R, and their application to psychiatric populations. To facilitate comparisons across clinical studies, effect sizes for each study were calculated based on reported binding values. The results obtained will be discussed in relation to radioligand characteristics and other methodological issues.
Radioligands for the D1-receptor
One of the first D1-R selective compounds to described was SCH 23390 [22] , with in vitro KD values of between 0.14-0.8 nM in rats [23] , and 0.35 nM in the human brain [24] . The compound was radiolabelled with 11 C in 1986 [25] , shortly thereafter applied in non-human primates and humans [26, 27] , and has since been the most frequently used D1-R radioligand in clinical studies. 23390, as well as higher specific to nonspecific binding ratio [29] . A disadvantage of the higher affinity is the slower kinetics, which means that a longer scanning time is required compared to [30, 31] . Autoradiography studies have shown cerebellum to be devoid of D1-R [40] , confirming that this region may serve as reference for estimation of free and non-specifically bound radioligand concentration in tissue (= non-displaceable uptake). In initial human studies using [ or by calculating a ratio of specific (target -reference region) and reference region radioligand uptake either for the whole measurement [42] or at transient equilibrium [43] . (VND), with VT in cerebellum as an estimate of VND). High reliability was shown for DVR whereas reliability was low for VT [44] . In the same paper, non-displaceable binding potential (BPND, corresponding to ratio of specific over non-specific binding at equilibrium [45] ) was estimated using a linear approach (Logan non-invasive) with cerebellar activity as input function, showing equal or higher reliability than DVR [44] . Subsequently, kinetic modelling using the simplified tissue reference model (SRTM) with cerebellum as reference input was validated for [ 11 C]SCH 23390 [31, 46] . In test-retest studies, absolute variability for BPND obtained using this approach has shown to be 4.6-8.4% for striatal regions and 9. to decline by around 7-9% per decade in striatum and 8-14 % in cortex [48] [49] [50] . In adolescents a similar rate of decrease was found for dorsal striatum (8%), whereas frontal cortical receptor levels showed a more rapid declince corresponding to around 26% per decade [51] . Hence, age is an important confounder in clinical studies, in particular when examining cortical regions in younger samples. Moreover, for both these radioligands part of the binding in cortical regions is explained by 5HT2a receptor binding, despite showing more than 100-fold higher affinity for D1-R in vitro [23] . In a study on non-human primates, where blocking was performed using the selective 5HT2a
antagonist MDL 100907, both radioligands showed a 25% reduction in binding. For [
this was subsequently confirmed in a human blocking study, showing that specific binding in cortical regions was reduced by 20-30%, whereas striatum showed no change [52] .
Application of D1-receptor PET in psychiatric disorders

Schizophrenia
Aberrations in DA neurotransmission has long been considered a key disease mechanism in schizophrenia, based on observations since several decades of an antipsychotic effect by drugs with D2-R antagonist properties [42, 53, 54] . Compared to D2-R, D1-R is not a major target for antipsychotic drug action. Whereas most antipsychotics show a 70-85% D2-R occupancy at clinically effective doses [54] , D1-R occupancy has generally been much lower, ranging from 0-16% for typical antipsychotics [42, 55] to 33-59% for the atypic antipsychotic drug clozapine [42, 56, 57] . Moreover, drugs specifically targeting the D1-R have shown limited efficacy and in some cases even a deterioration in patients [58] .
With regard to examining alterations in DA-R in patients, a series of studies on D2/D3-R have been performed dating back to the 80's, mainly in schizophrenia. A metaanalysis showed a small-tomedium increase in striatal receptor levels in schizophrenia patients [1] , however this effect was not evident when including only studies in antipsychotic-naïve patients. This observation is in line
with experimental data showing that antipsychotic treatment increases D2-R [59, 60] . For extrastriatal regions such as thalamus, decreases have also been shown [61, 62] . The main rationale for investigating D1-R in schizophrenia has been that frontal cortex is considered a key region in cognitive neuroscience models of the disorder [63, 64] , and that cognitive domains involving D1-R function in this region show clear deficits in patients [11] [12] [13] [14] 19] .
In the following review of PET D1-R studies in psychiatric disorders, effect sizes for comparisons between patients and control subjects were calculated using the formula for Cohens d:
. Notably, since individual-participant data was not available for any of the studies, the influence of confounders could not be taken into account, and the obtained values are therefore to be viewed as a rough estimate of the magnitude of difference.
In the first PET study evaluating D1-R in schizophrenia, [ 11 C]SCH 23390 was used to examine 18 patients and 17 healthy controls [65] . 10 of the patients were naive to antipsychotic drugs (DN), and the remaining 7 were drug free (DF) for a minimum of 2 weeks. BPND was calculated as a ratio between the rate constants k3/k4 as derived from 2TCM with metabolite-corrected arterial plasma as input function. A statistically significant decrease was found in prefrontal cortex (d = -1.0 for DN, -1.39 for DF, uncorrected for age), and binding in this region showed a negative association to negative symptoms and cognitive function as assessed using Wisconsin Card sorting. No significant difference was observed in the striatum (Table 1) . In order to exclude that the differences were due to 5HT2a-R binding, in a subsequent study [ 11 C]N-methylspiperone was used to examine 5HT2-R binding in the same cohort of patients. A trend-level reduction was observed in DF patients, but no difference in the DN subgroup was found, indicating that the reported decrease in
at least in the latter group was not explained by the contribution of 5HT2a [66] .
Subsequently, Abi-Dargham et al used [ 11 C]NNC 112 in 16 drug free patients with schizophrenia, of which 7 were drug naïve, and 16 control subjects [67] . The outcome measure used for D1-R binding was BPP, calculated VT-VND, with VT in target region estimated using 2TCM, and 1TCM cerebellum VT as VND. Binding was shown to be higher in cortical regions, reaching statistical significance for prefrontal cortex (d = 0.87) however no correction for multiple comparisons was applied (13 regions were tested). No difference was found in striatum (effect size 0.06). Moreover, D1-R binding in prefrontal cortex showed negative correlations to working memory task (n-back).
]SCH 23390 to examine 10 DN first episode patients with schizophrenia and 10 healthy control subjects [68] . Two examinations were performed, one with high and one with low specific radioactivity, allowing for estimation of receptor density (Bmax) and apparent affinity (KD) separately by use of a Scatchard plot. BPF, corresponding to specific binding compared to free plasma concentration, was calculated directly as Bmax/KD [69] . No statistically significant differences were found for any region, with an average effect size of BP in striatal regions of -0.36, and for cortical regions 0.33. No statistically significant difference between groups was found for Bmax or KD.
In a Finnish twin study, [
11 C]SCH 23390 was used to estimate D1-R in 9 patients with chronic schizophrenia compared to that of 11 healthy co-twins of patients, as well as 13 healthy control twins (independent twin pairs) [70] . BPND was quantified using the SRTM, for striatum as well as a Given that these somewhat conflicting results in schizophrenia patients were obtained using different radioligands, Kosaka et al investigated a group of six patients in residual phase and 12 age-matched control subjects using both [ 11 C]NNC 112 and [ 11 C]SCH 23390 [71] . In all patients, previously used antipsychotics were discontinued and changed to sulpiride, which is a selective D2/D3-R antagonist with low affinity for D1-R [72] . For both tracers, BPND was calculated using the SRTM, with cerebellum as reference region. The correlation between D1-R binding for the two schizophrenia patients, all of whom were drug-free, and 12 drug-naïve [73] . Data was quantified using 2TCM for target regions and 1TCM for cerebellum, using distribution volumes to derive BPP as described above, as well as BPND ((VT -VND)/VND). A significant increase was found in all cortical regions in drug naïve patients when using BPP as outcome measure (d = 1.03 for Of all studies on D1-R in schizophrenia, the two reports showing higher levels included only drugfree patients, with a substantial part of the patients being drug-naïve [67, 73] . Moreover, in studies where both drug-free and drug naïve patients were included, subgroup analyses showed that patients with previous antipsychotic treatment had numerically lower binding compared to patients without such exposure [73, 75] . Although these comparison were post-hoc (i.e. DN and DF patient were not matched) and therefore should be interpreted cautiously, the data is suggestive of a reduction in D1-R being caused by antipsychotic medication. This is in line with experimental post-mortem studies in non-human primates, showing a clear downregulation of D1-R density after treatment with classical D2-antagonists as well as clozapine, as assessed using both quantitative autoradiography and mRNA levels [76, 77] . Further support comes from the large decreases in D1-R observed in treated patients compared to healthy monozygotic co-twins [78] , which is striking considering the high ICC values reported between healthy control MZ twins (0.71-0.8 for striatum), paralleling data for D2/D3 that together suggest a largely genetic regulation of DA-R [79] .
In addition to studying drug-naïve patients, another approach to circumvent the confounding effects of medication is to investigate relatives to patients, or conditions showing a genetic overlap with schizophrenia, with the assumption that the shared genetic liability would translate to similarities in brain biochemical markers. In the twin study by Hirvonen et al, unaffected co-twins to schizophrenia patients showed higher cortical D1-R levels compared to healthy twins without an affected sibling [70] . The effect was tested statistically for monozygotic twins (n=6 vs n=13), reaching significance for some cortical regions (average d for cortical regions = 0.66) whereas no significant difference was found for striatum (d= 0.33). Additional evidence in favour of a role of increased D1-R in psychosis comes from a study in schizotypal personality disorder, a condition sharing genetic risk with schizophrenia, where higher prefrontal D1-R availability as assessed using BPF and BPP was associated with poorer working performance [80] .
Affective disorders
In patients with affective disorders, PET studies on the DA system have mainly focused on D2-R, showing inconclusive results [4] . In contrast, studies on D1-R have been more scarce. Suhara and colleagues used PET and [ 11 C]SCH 23390 in 21 healthy control subjects and 10 bipolar patients, of which 3 experienced a depressive episode, one a mild manic episode, and 6 were euthymic [81] . 
Obsessive-compulsive disorder
There are two published papers on D1-R in obsessive-compulsive disorder (OCD), based on the same sample of 7 drug free OCD patients and 7 healthy control subjects investigated using [ 11 C]SCH 23390. In the first report, caudate and putamen were used as primary regions of interest [84] , and in a subsequent publication the analysis was extended to include the anterior cingulate cortex (ACC) [85] . When describing the method of quantification, the authors state that cerebellum was used as a reference region, citing Lammertsma et al. (1996) which describes the SRTM, but then Logan graphical analysis is given as the method used to obtain distribution volume ratios.
However, this approach requires an arterial input function [86] and there is no information given on collection of arterial samples. Moreover, if a linear method was indeed used, it is not clear if the analysis was restricted to a range after the equilibrium time, and if so which t* was used. research [87] . Given these uncertainties, the results from this study should be interpreted with caution.
Substance abuse disorders
The DA system has long been of central interest in research on drug addiction. PET research has focused primarily on the D2/D3-R, and to date only two studies have investigated D1-R. In a study [89] . Regions included in the primary analysis were functional subregions of the striatum as well as a range of cortical regions, and quantification was performed as in [88] . No statistically significant difference was observed between patients and control subjects, in striatum (d = 0.11 (BPP) and -0.26 (BPND)), or cortical regions ( -0.1 and -0.49). A significant correlation was observed between D1-R BPND in ventral striatum and the choice for cocaine at the 6 mg level, but no relationship was found for any other subregion, when using BPP as outcome measure, or when analysing behavioural data for higher doses.
Discussion
Compared to other markers of the DA system, only a limited number of studies have investigated D1-R in psychiatric disorders. In schizophrenia, which is the most studied condition with a total of
83 identified unique patients, results have been somewhat discrepant. Although studies were not designed to specifically investigate the effect of antipsychotic medication, the data strongly suggests that antipsychotic drugs cause a decrease in D1-R, an observation which is in line with non-human experimental data [76, 77] . When taking this confounder into account, the overall evidence is in favour of higher levels of D1-R in frontal cortical regions in patients suffering from psychosis symptoms. Differences in quantification methods and small sample sizes limit the conclusions that can be drawn, but if replicated, the results may indicate a specific role of D1-R in psychosis, alternatively they may reflect an upregulation in response to a reduction in cortical DA release [90, 91] . For affective disorders, a lower striatal D1-R levels is suggested in depression, as well as reductions in cortical D1-R in bipolar patients. However, the total sample size for these conditions is considerably smaller than for schizophrenia and the results should be viewed as preliminary. Similarly, the higher D1-R levels shown in frontal cortex for chronic ketamine users is in need for replication.
A number of factors have to be considered when interpreting the data. With existing PET radioligands, it is not possible to obtain a fully unbiased measure of cortical D1-R. 5HT2a-R receptor binding may account for around 25% of the cortical binding for both [ [23, 52] , which reflects that 5HT2a-R shows about two-fold density compared to D1 in cortical regions in nonhuman primates [92] and has shown to be abundant also in human cortex [93] . 5HT2a-R has shown to be implicated in both schizophrenia and depression based on genetic associations and gene expression data [94] [95] [96] , and both established and more recently developed antipsychotics show an affinity for 5HT2a [97, 98] . In schizophrenia, the follow-up study by Okubo et al showed trend-level lower 5HT2 binding as measured using PET and [ 11 C]NMSP in neuroleptic-treated patients, which could have contributed to the observed decreases in [ 11 C]SCH 23390 binding, whereas no difference was found in drug-naïve patients [66, 65] . Subsequently, lower binding of the 5HT2-R radioligand [ 18 F]altanserin was shown in a sample of 30 drug-naïve patients compared to control subjects [99] . Hence, it cannot be excluded that differences in 5HT2a-R density may have influenced the results for cortical regions in schizophrenia. In contrast, striatal 5HT2a-R density is 2-3 fold lower than striatal D1-R [40, 100] and blocking of 5HT2a-R did not affect binding of either [ 11 C]SCH 23390 or [ 11 C]NCC 112 in striatal regions, confirming that the influence of 5HT2a-R in this region should be negligible.
For D2/D3-R antagonist radioligands such as [ 11 C]raclopride, sensitivity of binding to endogenous DA levels is well-documented [101, 102] . For D1-R radioligands, ex vivo studies in rodents have
shown no effect on [ [108] . For the D2/D3-R, agonist radioligands have shown increased sensitivity to endogenous DA levels compared to antagonist radioligands [109] . One potential explanation is that D2/D3-R may exist in an active (G-protein-coupled state) and an inactive state, and that agonist radioligands only bind to the active state resulting in a larger degree of displacement by endogenous ligands. With regard to the D1-R, the agonist radioligand (S)-[11C]Nmethyl-NNC 01-0259 failed to show any differences in response to amphetamine-induced DA release [110] . Taken together, the available evidence does not support endogenous DA as a confounding factor in D1-R PET studies. Possible explanations for this lack of sensitivity to endogenous DA is the lower affinity for DA [10] , a large degree of extra-synaptic receptor location [111, 112] or that only a small fraction of dopamine D1-like receptors exist in the high-affinity state [113] . ]SCH 23390 used 2TCM-derived rate constants to estimate BPND [65, 81] , an approach which has shown to be unsuitable for most radioligands [114, 115] . For and accuracy [44] , which may be due to the rapid metabolism of this tracer in plasma [116] . For three studies using [ 11 C]NCC 112, results were reported using both BPP and BPND. In the study on schizophrenia by Abi- Dargham et al. (2012) , statistically significant increases in patients compared to control subjects were found only for BPP, however comparison of effect sizes between outcome measures was not possible since BPND values were not reported. Notably, BPP relies on the
assumption of no differences in protein binding of the radioligand [45] , which was trend-level different between groups. In the two remaining studies employing both BPP and BPND, both in substance use disorders, the outcome measures gave slightly different effect sizes [88, 89] (Table 1) .
A potential explanation for these differences could be that even minor group differences in VND would cause a relatively larger impact on BPND compared to BPP, since it is included in the denominator [73] .
One important general caveat that needs to be considered in the reviewed studies are the small sample sizes used. In 6 out of the 11 studies, only 10 or fewer patients were included. Given the difference in sample sizes, effect sizes were calculated to allow for an informal synthesis of the data, instead of comparing p-values. However, since the analysis was based on summary statistics, confounding variables were not possible to take into account in this analysis.
Low power is a problem in neuroscience research in general, and for neuroimaging in particular, and can lead to both false negative and false positives [117] . Since PET is an expensive method and also involves radiation exposure, an important way forward for D1-R research in psychiatric populations would be to share data [118] . This can be done at the level of outcome measures to allow for an individual participant data meta-analysis, which makes it possible to take confounders such as age, medication and radioligand used into account in a more formal way (Plavén Sigray et al. in review). Alternatively, if raw data is shared this would also solve some of the methodological confounders by allowing for a harmonized re-analysis. Arguably, data sharing may be particularly important in research on the pathophysiology of psychiatric disorders, where disease heterogeneity is often considered to be high.
In summary, PET studies using radioligands for the D1-R has shown some promise as a means of investigating the DA system in psychiatric disorders. Additional work in larger sample sizes, ideally with more selective radioligands, are needed to evaluate D1-R as a candidate disease biomarker that could eventually be used to inform treatment.
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